Shopping Cart
- Remove All
Your shopping cart is currently empty
Renzapride (BRL 24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist.Renzapride can be used in the study of constipation-predominant irritable bowel syndrome (C-IBS).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $89 | In Stock | |
| 2 mg | $133 | In Stock | |
| 5 mg | $223 | In Stock | |
| 10 mg | $398 | In Stock | |
| 25 mg | $768 | In Stock | |
| 50 mg | $1,050 | In Stock | |
| 100 mg | $1,420 | In Stock | |
| 200 mg | $1,890 | In Stock |
| Description | Renzapride (BRL 24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist.Renzapride can be used in the study of constipation-predominant irritable bowel syndrome (C-IBS). |
| Targets&IC50 | 5-HT4 receptor:115 nM (Ki) |
| In vitro | Renzapride was selective for serotonergic receptors and, in particular, had high affinity for human 5-HT(3) and guinea-pig 5-HT(4) receptors (K(i) 17 and 477 nm, respectively)[1]. |
| In vivo | Renzapride(BRL 24924)(0.5-1 mg/kg) and another 5-HT1P antagonist, N-acetyl-5-hydroxytryptamine-5-hydroxytryptamine amide (5 mg/kg), significantly increased the rate of emptying of 51Cr-labeled liquid meals from the mouse stomach[2]. |
| Synonyms | BRL 24924 |
| Molecular Weight | 323.82 |
| Formula | C16H22ClN3O2 |
| Cas No. | 112727-80-7 |
| Smiles | COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN2CCC[C@@H]1C2 |
| Relative Density. | 1.30 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL (30.88 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.09 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.